CGENNasdaq

COMPUGEN LTD

Healthcare·Oncology·Phase 1·Holon, Israel
Oncology

COMPUGEN LTD (CGEN): 5 pipeline candidates · 2 upcoming catalysts · ~13 mo cash runway · 3 clinical trials. Updated within the last hour.

5.4/10

BioSniper Score

6-factor signal · derived from public data

Cash Runway3.6

12.8 months

Financial Health10.0

0% dilution

Pipeline Maturity6.0

Lead: Phase 1/Phase 2

Pipeline Breadth8.5

5 candidates

Catalyst Momentum4.0

2 upcoming, next in ~286d

Insider Signal0.0

0 buys · 10 sells (180d)

A transparent, data-derived signal for COMPUGEN LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$188.2M

Cash

$90.6M

Quarterly Burn

$32.2M

Runway

12.8 mo

Revenue

$72.8M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Jul 2027
Today~14 mo out
Catalyst within runway

Pipeline (5 candidates)

Upcoming Catalysts (2)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

75

Total value held

$28.5M

HolderSharesValue
silverarc capital management, llc3,315,845$7.1M
renaissance technologies llc1,632,988$3.5M
morgan stanley1,053,229$2.2M
ark investment management llc1,049,873$2.2M
nomura asset management international inc.1,020,000$2.2M
northern trust corp650,868$1.4M
two sigma investments, lp521,587$1.1M
state street corp415,366$885K
ubs group ag306,708$653K
wells fargo & company/mn3,100$646K

Showing top 10 of 75 institutional holders of COMPUGEN LTD. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

3 clinical trials·CEO: Dr. Eran Ophir Ph.D.

Frequently asked questions

How many drug candidates are in COMPUGEN LTD's pipeline?

COMPUGEN LTD (CGEN) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is COMPUGEN LTD's lead drug candidate?

COMPUGEN LTD's most advanced tracked candidate is cohort expansion (Phase 1) for Advanced Cancer.

What is COMPUGEN LTD's next catalyst?

COMPUGEN LTD's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: com701" — expected March 31, 2027.

What is COMPUGEN LTD's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, COMPUGEN LTD has approximately 12.8 months of cash runway.

What is COMPUGEN LTD's market capitalization?

COMPUGEN LTD's market capitalization is approximately $188.2M.

Get the full picture on COMPUGEN LTD

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.